Photocure ASA

Report Publication Announcement • Dec 15, 2015

Photocure: Presentation at DNB's 6th Annual Health Care Conference in Oslo

Photocure: Presentation at DNB's 6th Annual Health Care Conference in Oslo

Oslo, Norway, December  15, 2015: Photocure (OSE: PHO), a specialty

pharmaceutical company focused on photodynamic technologies in cancer and

dermatology, will present a company overview at DNB's 6(th) Annual Health Care

conference today, December 15, 2015, at 3:50 pm CET. Kjetil Hestdal, President

and CEO will be presenting on behalf of Photocure.

Please find the presentation attached.

For further information, please contact:

Photocure

President & CEO Kjetil Hestdal

Tel: + 47 913 19 535, Email: kh@photocure.no

CFO Erik Dahl

Tel: +47 450 55 000, Email: ed@photocure.no

About Photocure ASA

Photocure ASA, headquartered in Oslo, Norway, is a specialty pharmaceutical

company and world leader in photodynamic technology. Based on our unique

proprietary Photocure Technology(®) platform, Photocure develops and

commercializes highly selective and effective solutions in disease areas with

high unmet medical need, such as bladder cancer, HPV and precancerous cervical

lesions, colorectal cancer and skin conditions. Our aim is to provide solutions

that can improve health outcomes for patients worldwide. Photocure is listed on

the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at

www.photocure.com.

This information is subject of the disclosure requirements acc. to §5-12 vphl

(Norwegian Securities Trading Act)

[HUG#1973517]